Ben is Founder, Chairman & CEO of Foresee Pharmaceuticals. Foresee was founded as a research division of QPS and spun-off in 2011. Ben founded QPS in 1995 and now employs more than 1170 people at 9 facilities in the Delaware (US), Missouri (US), Florida (US), North Carolina (US), North Dakota (US), Groningen (The Netherlands), Graz (Austria), Hyderabad (India), and Taipei (Taiwan). QPS is the recipient of “2013 Company of the Year Award” by Delaware Bioscience Association. “CEO of 2015 Award” by Finance Monthly. Ben also co-founded Theracore Pharmaceuticals, Inc. in 2003. Its radiopharmaceutical division was subsequently spun-off to form Avid Radiopharmaceuticals, Inc. in 2005. Avid was acquired by Eli Lilly in late 2010 for $880 million. Its leading imaging agent Amyvid was approved in April, 2012.
Ben obtained his Ph.D. in analytical chemistry (mass spectrometry) from the University of Michigan at Ann Arbor with Prof. David M. Lubman. Ben is the co-inventor of a novel Ion Trap/Time-of-Flight Mass Spectrometer. The publication of this work was selected as “Best Student Paper of 1994”, awarded by International Journal of Mass Spectrometry and Ion Physics. Ben began his pharmaceutical career at DuPont Merck Pharmaceutical Co. in the Drug Metabolism and Pharmacokinetics Section, where he built the LC/MS/MS group dedicated to supporting drug discovery, preclinical and clinical studies. In 1996, Ben received the Summit Award, the highest level of achievement at DuPont Merck for his dedicated contribution to the development of Efavirenz, an anti-viral drug approved by the FDA for the treatment of HIV disease.

Max Chan is a seasoned Chief Financial Officer with capital/fund raising, IPO planning and execution experience; in addition, Max is well connected with investor community. The expertise, knowledge and experience that Max brings to Foresee will further strengthen our capacity in the commercial planning strategies and executions. After working at China Development Industrial Bank (1992~2000) and Intel Capital (2000~2004), Max joined Himax (Nasdaq: HIMX) in 2004 and served as their CFO until 2010, when he switched to the biopharmaceutical sector and served as CFO in Taigen Biopharmaceutical, JHL Biotech and OBI Pharma from 2010~2019; Max had played an integral role in numerous strategic initiatives, including IPO, funding raising, licensing, and M&A. Max Chan received his BS degree in Civil Engineering and MBA degree in Finance from the National Taiwan University and received another MS degree in Business Administration from the University of Illinois at Urbana Champaign, USA.

Dr. Yisheng Lee brings extensive leadership experience in patient care, new drug clinical trial execution and medical research that will help build Foresee's competitive advantage in the implementation of clinical development strategies and trial designs.  Dr. Lee has practiced pediatric hematology/oncology and held multiple academic appointments (teaching and research) at Harvard, Duke, Stanford, and UCSF Medical Schools over the past 30 years.  Dr. Lee received a medical doctor degree as an honor graduate from National Taiwan University, a Ph. D. in Tumor Immunology/Pathology from Duke University, and an MBA from UC Irvine.  Dr. Lee has first-hand patient caring insights and solid academic achievements in pathology, neurology, pediatrics, hematology, and oncology. 

Dr. Jagdish Parasrampuria has over 30 years of drug development experience at large pharmaceutical companies including Janssen (J&J), Abbott (now AbbVie), and Wyeth (now Pfizer) as well as biotech companies. He has led development of solids, parenterals as well as novel dosage forms. He was the CMC lead for several IND/NDA/BLA submissions, and has extensive experience interacting with regulatory authorities for new drug approvals. He holds 4 patents and has authored over 60 publications and abstracts including 4 book chapters. He received his BS in Pharmacy (gold medalist) from Mysore University, MS in Pharmaceutics from Nagpur University, and PhD in Pharmaceutics from the University of Houston.

Dr. Li is currently serving as Chief Technology Officer at Foresee Pharmaceuticals, Co., Ltd and is responsible for R&D strategic planning, R&D budget and daily operational activities. Dr. Li has a proven track record of successful pharmaceutical product development from concept to bench to bedside, and has been actively involved in the filing of 4 INDs. Dr. Li has more than 21 years of pharmaceutical industrial experience in the field of drug delivery and pharmaceutical product development.Dr. Li was previously Director of Formulation R&D at QPS, LLC, where he was responsible for product research and development. He is a co-inventor for the novel controlled release drug delivery platform technology that Foresee Pharmaceuticals, Inc. is founded on. Prior to joining QPS, Dr. Li worked for FeRx Incorporated from May 1999 to June 2004 where he was a principal scientist leading a research team to develop magnetically targeted drug delivery systems. Dr. Li was also responsible for the chemistry, manufacture and control (CMC) development resulted in a successful filing of an IND with U. S. FDA. He also contributed significantly to an IND approved by China's State Drug Administration (SDA). In addition, Dr. Li was also awarded two SBIR grants from NIH during his tenure at FeRx. From 1997 to 1999, Dr. Li was a Senior Scientist at GeneMedicine Inc. working in the area of gene delivery and formulation development. Dr. Li received his Ph.D. in Chemistry from Clemson University, South Carolina, and his post-doctoral training in Chemistry from the University of North Carolina/Glaxo-Wellcome, Inc., North Carolina.

Dr. Yang has over three decades of experience in drug discovery and preclinical development of small molecules and antibody-drug-conjugates in antiviral, anti-inflammatory, neuroscience, metabolic and oncology therapeutic indications.
Prior to joining Foresee, Dr. Yang was Co-founder and VP of Research at Aldea Pharmaceuticals, where he led the efforts of raising series-A financing (US $11 MM), establishing the research team, setting up the company infrastructure and facility, and advancing the company’s lead program into clinical development. He also contributed to Aldea’s series-B financing (US $24 MM). He previously served as Vice President of Chemistry at Eiger BioPharmaceuticals, where he oversaw research and manufacturing functions. He also served as Director and Head of Medicinal Chemistry at Sunesis Pharmaceuticals, where he was responsible for scientific team management and multiple medicinal chemistry programs, including new technology development, hit identification, and lead optimization to development candidate selection. Before joining Sunesis, Dr. Yang was a Research Scientist at Gilead Sciences, and a postdoctoral research associate at The Scripps Research Institute. Dr. Yang has authored 26 peer-reviewed manuscripts and is an inventor of 28 U.S. issued patents and several additional pending patents.
Dr. Yang received his B.S. in Chemistry from the Chinese Culture University, and his M.S. and Ph.D. in Organic Chemistry from the University of California, Riverside.

Dr. Boudreau brings extensive leadership experience in biotechnology and specialty pharmaceuticals companies. Most recently he was Vice President, Corporate Development & Licensing and member of the Executive Committee at Telesta Therapeutics, where he led several strategic transactions, including a significant license agreement for its Phase 3 uro-oncology program with global specialty pharmaceutical company, Ipsen. Dr. Boudreau has amassed broad corporate business development experience that covers the entire transaction lifecycle. He has successfully led and played key roles in both early and late stage/commercial product in-licensing/out-licensing, mergers and acquisitions, corporate strategy, venture creation and operations. Prior to Telesta, Dr. Boudreau was Director, Search & Evaluation - Business Development at Pendopharm, Director, Business Development & Strategic Planning at Pharmascience Inc., and Director, Business Development at Aegera Therapeutics Inc., which was acquired by Pharmascience Inc. in 2011. Dr. Boudreau started his career in business development as co-founder of a diagnostics company. He holds a Ph.D. in Neuroscience from McGill University and a B.Sc. in Biochemistry from the University of Montreal.

Bassem is a board-certified surgeon with over 18 years of diverse experience in clinical practice and the pharmaceutical industry, including Amgen, FibroGen, and Blade Therapeutics. Bassem brings a unique blend of medical expertise and leadership to the field. Throughout his career, he has successfully navigated the intersection of medicine and research, holding pivotal roles that span clinical development, regulatory interactions, and strategic decision-making. At Amgen, Bassem orchestrated the clinical development of PARSABIV and IMLYGIC programs, leading to their global approvals. He has also played a pivotal role in advancing several BiTE Immune-Oncology programs, targeting solid tumors across various phases of development. He had many years of experience leading multiple health agencies in face-to-face interactions and negotiations, resulting in an agreement on four Clinical Development Plans for Phase 2 and 3 clinical studies across several indications of Cudetaxestat (ATX inhibitor) and Pamrevlumab (mAB).
Bassem's earlier roles have further enriched his journey. He worked as an active surgeon at UCLA, immersing himself in the clinical intricacies of surgery. Additionally, his tenure as a Clinical Instructor and Medical Director for the KRAS oncogene program allowed him to delve into the complexities of targeted therapies for refractory colorectal cancer. Bassem's educational foundation is solidified by rigorous training, including a comprehensive general surgery program at the esteemed Brooklyn Hospital Center and an Internship at SUNY Downstate Medical Center in Brooklyn, New York.
In a pivotal phase of Bassem’s career, he spent over 5 years collaborating with a Contract Research Organization (CRO), contributing to Phase 2/3 studies in retinal diseases.

Dr. Bill Miller is the Vice President of Regulatory Affairs at Foresee Pharmaceuticals. Dr. Miller brings a broad range of experience in regulatory strategy, health authority interactions, and program leadership. Prior to joining Foresee Pharmaceuticals, Dr. Miller worked as a consultant for numerous pharmaceutical and biotech companies for their IND/NDA/BLA filings (US) and as their global regulatory lead for health authority applications for small molecules, biologics and biosimilars. Dr. Miller also was the global regulatory lead for several of CSL Behring’s approved immunodeficiency products, and served as the US regulatory lead for Teva Pharmaceuticals. He received his BS in Physics from Bloomsburg University of PA and PhD in Bioengineering from  University of Pennsylvania.

Dr. Chao-Pin Lee has more than thirty years of experience in pharmaceutical industry with 30+ patent applications and publications in peer-reviewed journals. A significant portion of Dr. Lee’s career was engaged in evaluating and developing technologies to support the pharmaceutical industry. For the evaluation of technologies, Chao-Pin served as the chairperson for the Drug Delivery Technologies Steering Team in GSK. This cross-functional and international steering team provided critical support to extend the life-cycle of key GSK products. At the most recent role as the COO for AIBIOS, Chao-Pin served as the project leader for a small molecule drug project for the treatment of inflammatory diseases.  Additionally, he worked with TAcc+ program of Taiwan to identify diagnostic, medical device, and AIoT related technologies. The object for this effort was to build a total healthcare ecosystem that consist of innovative technologies to provide comprehensive support to patients from early diagnosis, prevention, treatment to monitoring and analysis of disease progression.